ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0055

Activating STAT3 Mutations in CD8+ T Cells Correlate to Serological Positivity in Rheumatoid Arthritis
Abstract Number: 0056

Association of Soluble Immune Checkpoint Proteins with the Risk of Developing RA in ACPA-positive At-risk Individuals
Abstract Number: 0057

Flow Cytometry of Cells Within Induced Sputum from Individuals At-Risk for RA Reveals Relative Expansion of Small Macrophages
Abstract Number: 0058

Bradykinin Receptor B1 Blockade Suppresses Soluble CD13-Induced Differentiation of Osteoclasts from Monocytes
Abstract Number: 0059

Fragment Crystallizable (Fc)-Free Certolizumab Pegol Is Not Bound by Rheumatoid Factors, While Fc Containing Biological DMARDsAre, Driving ImmuneComplex Formation and Cellular Clearance
Abstract Number: 0060

Spectral Cytometry Shows Increased CD56hi NK Cells and New HLA-DR+CD56+ Phenotypes in RA
Abstract Number: 0061

Comparative Transcriptional Profiling of IPF and RA-ILD Lung Tissue Demonstrates Both Overlapping and Distinct Cell-specific Signaling Pathways
Abstract Number: 0062

Pro-Fibrotic Effects of Malondialdehyde-Acetaldehyde-Adducted and/or Citrullinated Proteins on Macrophages and Human Lung Fibroblasts
Abstract Number: 0063

Splicing into Action:Investigating the Role of Alternative Splicing in Rheumatoid Arthritis Neutrophils
Abstract Number: 0064

Anti-Citrullinated Protein Antibodies Arise During Affinity Maturation of Germline-Encoded Antibodies to Carbamylated Proteins in Rheumatoid Arthritis
Abstract Number: 0065

Evidence of Membranolytic Targeting and Intracellular Citrullinationin Neutrophils Isolated from Patients with Rheumatoid Arthritis
Abstract Number: 0066

Association Between Gut Microbiota, Inflammation, and Epigenetics in Rheumatoid Arthritis Patients
Abstract Number: 0067

Psoriasis Patients at Risk for Psoriatic Arthritis Have Increased Levels of Circulating Pro-migratory Dendritic Cells
Abstract Number: 0068

Enhanced Expression of GPR65 in Inflammatory Sites and Bone Formation Regions in Ankylosing Spondylitis: Evidence from ScRNA-seq Analysis
Abstract Number: 0069

Activation of Cardiovascular Inflammation and Wnt Signaling in Spondyloarthritis: Insights from the HLA-B27 Transgenic Rat Model

« Previous Page
1
…
5
6
7
8
9
…
182
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].